Hoth Therapeutics (NASDAQ:HOTH) Stock, Quote.Headers.trade-ideas

Hoth Therapeutics

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AVGO

BLMZ

BOWL

CLNN

EAST

FFIE

GWRE

HOTH

SIFY

SWBI

TDUP

WHLR

Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Gold-image

Earnings

Equities

Eurozone

Commodities

APLD

CHPT

NSSC

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SAIC

Gold Moves Higher; Science Applications International Posts Upbeat Earnings

Crude-oil-4-logo

SGLY

Dow Tumbles 1%; US Crude Oil Stocks Fall

Hoth Therapeutics Inc

JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

DBVT

JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $5 Price Target

WIIM

AutoZone shares are trading lower after the company reported worse-than-expected Q4 financial results.

Federal Reserve

Fed's Bowman Says Risk Of Litigation Post-Chevron Ruling Is Already Chilling Regulatory Agencies And Is An "Excellent Influence" On Overreach; Hard For Fed To Measure The Impact Of Immigration On The Labor Market

REGN

Regeneron Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $1175 to $1077.

JMP Securities analyst Trevor Walsh reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Market Outperform and maintains $400 price target.

CRWD

JMP Securities Reiterates Market Outperform on CrowdStrike Holdings, Maintains $400 Price Target

Needham analyst Laura Martin reiterated a buy rating on Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and a <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings" target="_blank" rel="noreferrer noopener">$260 price target</a>.
The price target is based on a Discounted Cash Flow (DCF) where Martin used a cash tax rate of 15%, a weighted average cost of capital&nbsp;(WACC) of 8.8%, and a long-term nominal GDP growth rate of 2%.
Martin projects that Apple&#8217;s up-selling of devices, including wearables, accessories, iPads, Macs, and Vision Pro, will represent about $97 billion of revenue in fiscal 2025.
Assuming 50%- 80% churn out implies that an additional 50%- 80% of $97 billion of revenue is dependent on the iPhone, which would add an incremental 12% %- 19%. In total, these numbers imply that 89%- 96% of Apple&#8217;s fiscal 2025 revenue depends on the iPhone — a single product.
Apple&#8217;s valuation should be partly based on its growth outlook, Martin says. 
The analyst also flagged investor concerns over paying a 30 times fiscal 2025 price-to-earnings multiple (P/E) for Apple. The Cupertino, California-based company&#8217;s revenue grew 2% in fiscal 2024 and shrank by 3% in fiscal 2023.
The re-rating reflects investors&#8217; need for a safer liquid stock during 2025. Four big tech companies are splurging in large language models (LLMs) and other GenAI infrastructure. They include:
<ul>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>Alphabet Inc (NASDAQ GOOGL)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and </li>
<li>Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).</li>
</ul>
The problem is there&#8217;s no visible revenue upside, Martin adds.
<h3 class="wp-block-heading">Apple 2025 Revenue Is Reliant On The iPhone</h3>
Apple is shrinking its equity base by buying shares. The iPhone maker is also driving 11% EPS growth in fiscal 2025 and 12% in fiscal 2026. Apple has committed to achieving &#8220;net cash zero&#8221; from about $50 billion of net cash on its balance sheet on June 30.
Apple reported an operating cash flow of about $91 billion for the first nine months of fiscal 2024. This implies accelerating share repurchases, the analyst added.
The best way to think about Apple&#8217;s valuation and pricing power is to consider its installed base: more than 1.25 billion of the wealthiest consumers in the world using over 2.2 billion active devices (as of Dec. 31, 2023) an average of about five hours per day.
The analyst noted that Apple aims to grow LTV (lifetime value) by increasing the average revenue per user and lowering churn levels by upselling its users on additional devices and services.
Over time, Apple has added new products and services that drive stickiness and ecosystem lock-in.
Of Apple&#8217;s fiscal 2025 revenue of $420 billion, she projects that iPhone revenue will be $215 billion, or 51%. Apple says it has about 2.2 billion active devices and about 1.3 billion unique users, suggesting an average of about 1.7 iOS devices per user. 
But the iPhone is the &#8220;anchor&#8221; product and millions of consumers own only an iPhone, as per the analyst.
Martin noted that 100% of services revenue of $108 billion in fiscal 2025 (i.e., 26% of total revenue) is dependent on owning an iPhone. Together, these two buckets imply that 77% of Apple&#8217;s fiscal 2025 revenue is reliant on the iPhone.
Price Action: AAPL stock is up 0.71% at $228.08 premarket at last check Tuesday.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41001128/this-bp-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday">This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday</a></li>
</ul>
Image: Unsplash

Tech

AAPL

AMZN

MSFT

Apple iPhone To Fuel 96% Of 2025 Revenue, Analyst Says: A Safer Bet Than AI-Heavy Amazon, Alphabet, Microsoft, Meta?

JP Morgan analyst Tien-Tsin Huang maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Overweight and lowers the price target from $376 to $370.

JP Morgan Maintains Overweight on Accenture, Lowers Price Target to $370

Truist Securities analyst Youssef Squali reiterates Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Buy and maintains $76 price target.

ETSY

Truist Securities Reiterates Buy on Etsy, Maintains $76 Price Target

Management

PARA

PARAA

Paramount Global Says To Begin Phase Two Of Workforce Reductions In US; After Today, 90% Of Workforce Reductions Will Be Complete

JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Overweight and raises the price target from $14 to $17.

REPL

JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $17

McKesson shares are trading lower after Baird downgraded the stock from Outperform to Neutral and lowered its price target from $603 to $531.

BNTX

BioNTech shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $93 to $145.

Truist Securities analyst Srikripa Devarakonda reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and maintains $1200 price target.

Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1200 Price Target

Macro Economic Events

Market Summary

Economics

General

SMAR

Benzinga Market Summary: China Announces Stimulus, Novo Nordisk CEO To Testify To Senate, Smartsheet To Be Acquired By Blackstone And Vista

AAR (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/air#NYSE">AIR</a>) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.66%. A quarter ago, it was expected that this airplane maintenance company would post earnings of $0.86 per share when it actually produced earnings of $0.88, delivering a surprise of 2.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
AAR, which belongs to the Zacks Aerospace - Defense Equipment industry, posted revenues of $661.7 million for the quarter ended August 2024, surpassing the Zacks Consensus Estimate by 2.46%. This compares to year-ago revenues of $549.7 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
AAR shares have added about 11% since the beginning of the year versus the S&amp;P 500&#39;s gain of 19.6%.
<h2>What&#39;s Next for AAR?</h2>
While AAR has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AAR: unfavorable. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.91 on $654.63 million in revenues for the coming quarter and $3.72 on $2.69 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Aerospace - Defense Equipment is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, FTAI Aviation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftai#NASDAQ">FTAI</a>), has yet to report results for the quarter ended September 2024.
This transportation infrastructure company is expected to post quarterly earnings of $0.77 per share in its upcoming report, which represents a year-over-year change of +133.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
FTAI Aviation&#39;s revenues are expected to be $429.29 million, up 47.5% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2340133/aar-air-tops-q1-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2340133">To read this article on Zacks.com click here.</a>

Earnings Beats

Large Cap

Mid Cap

FTAI

AAR Tops Q1 Earnings and Revenue Estimates

Barclays analyst Nicholas Campanella maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Overweight and raises the price target from $211 to $280.

Barclays Maintains Overweight on Constellation Energy, Raises Price Target to $280

MNSO

MINISO Group shares are trading lower after Jefferies downgraded the stock from Buy to Hold.

Deep-pocketed investors have adopted a bearish approach towards Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Carvana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable options, 6 are puts, totaling $179,184, and 2 are calls, amounting to $66,359.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $125.0 to $190.0 for Carvana over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Carvana's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Carvana's whale activity within a strike price range from $125.0 to $190.0 in the last 30 days. 
<h3>Carvana Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727185562_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$17.2</td>
<td>$18.0</td>
<td>$18.4</td>
<td>$190.00</td>
<td>$36.8K</td>
<td>22</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$5.8</td>
<td>$4.1</td>
<td>$4.5</td>
<td>$160.00</td>
<td>$36.0K</td>
<td>1.3K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$49.25</td>
<td>$48.55</td>
<td>$48.55</td>
<td>$125.00</td>
<td>$33.9K</td>
<td>316</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$7.6</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$167.50</td>
<td>$32.4K</td>
<td>284</td>
<td style="text-align: right;">58</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.6</td>
<td>$175.00</td>
<td>$26.8K</td>
<td>1.1K</td>
<td style="text-align: right;">156</td>
</tr>
</tbody>
</table>

<h3>About Carvana</h3>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
In light of the recent options history for Carvana, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Carvana</h3>
<ul>
<li>With a trading volume of 83,960, the price of CVNA is down by -1.41%, reaching $172.69.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 37 days from now.</li>
</ul>
<h3>What The Experts Say On Carvana</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $183.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $200. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Buy, setting a price target of $185. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a In-Line rating on Carvana with a target price of $157. 
&#x2A; An analyst from Stephens &amp; Co. has revised its rating downward to Overweight, adjusting the price target to $190. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Carvana with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

CVNA

Carvana's Options: A Look at What the Big Money is Thinking

Deep-pocketed investors have adopted a bullish approach towards Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Caterpillar. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $188,985, and 6 are calls, amounting to $225,314.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $350.0 and $420.0 for Caterpillar, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Caterpillar's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Caterpillar's whale activity within a strike price range from $350.0 to $420.0 in the last 30 days. 
<h3>Caterpillar 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727185557_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$5.05</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$350.00</td>
<td>$103.0K</td>
<td>2.0K</td>
<td>255</td>
</tr>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$27.05</td>
<td>$25.6</td>
<td>$27.05</td>
<td>$360.00</td>
<td>$67.6K</td>
<td>171</td>
<td>38</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$21.7</td>
<td>$19.6</td>
<td>$20.77</td>
<td>$390.00</td>
<td>$51.9K</td>
<td>3</td>
<td>48</td>
</tr>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.4</td>
<td>$4.35</td>
<td>$4.35</td>
<td>$400.00</td>
<td>$43.4K</td>
<td>3.5K</td>
<td>1.6K</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.55</td>
<td>$3.25</td>
<td>$3.4</td>
<td>$370.00</td>
<td>$34.0K</td>
<td>348</td>
<td>105</td>
</tr>
</tbody>
</table>

<h3>About Caterpillar</h3>
Caterpillar is the top manufacturer of heavy equipment, power solutions, and locomotives. It is currently the world's largest manufacturer of heavy equipment. The company is divided into four reportable segments: construction industries, resource industries, energy and transportation, and Cat Financial. Its products are available through a dealer network that covers the globe with about 2,700 branches maintained by 160 dealers. Cat Financial provides retail financing for machinery and engines to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Caterpillar product sales.
In light of the recent options history for Caterpillar, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Caterpillar Standing Right Now?</h3>
<ul>
<li>With a trading volume of 143,745, the price of CAT is up by 3.06%, reaching $382.51.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 35 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Caterpillar, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on Caterpillar: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bullish move on MicroStrategy. Our analysis of options history for MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) revealed 14 unusual trades.
Delving into the details, we found 35% of traders were bullish, while 21% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $191,154, and 9 were calls, valued at $1,035,028.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $380.0 for MicroStrategy over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in MicroStrategy's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to MicroStrategy's substantial trades, within a strike price spectrum from $110.0 to $380.0 over the preceding 30 days.
<h3>MicroStrategy Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727185552_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$46.0</td>
<td>$45.85</td>
<td>$46.0</td>
<td>$110.00</td>
<td>$427.8K</td>
<td>550</td>
<td>95</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$63.25</td>
<td>$61.5</td>
<td>$62.47</td>
<td>$138.00</td>
<td>$187.4K</td>
<td>186</td>
<td>0</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$62.5</td>
<td>$60.1</td>
<td>$61.21</td>
<td>$138.00</td>
<td>$183.6K</td>
<td>287</td>
<td>0</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$1.47</td>
<td>$0.82</td>
<td>$1.31</td>
<td>$140.00</td>
<td>$65.5K</td>
<td>3.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$29.1</td>
<td>$28.3</td>
<td>$28.3</td>
<td>$380.00</td>
<td>$56.6K</td>
<td>4.6K</td>
<td>20</td>
</tr>
</tbody>
</table>

<h3>About MicroStrategy</h3>
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.
Having examined the options trading patterns of MicroStrategy, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is MicroStrategy Standing Right Now?</h3>
<ul>
<li>With a trading volume of 431,799, the price of MSTR is up by 0.73%, reaching $151.06.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 36 days from now.</li>
</ul>
<h3>What The Experts Say On MicroStrategy</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $173.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Barclays downgraded its rating to Overweight, setting a price target of $146. 
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on MicroStrategy, maintaining a target price of $173. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on MicroStrategy, which currently sits at a price target of $200. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on MicroStrategy, which currently sits at a price target of $173. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MicroStrategy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

MSTR

Market Whales and Their Recent Bets on MSTR Options

Hoth Therapeutics announces JD with Wise Systems International

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the day with a breakdown of the biggest pre-market stock movers worth checking out on Tuesday morning!



Moving stocks are a share repurchase program, terminated contracts, public offerings and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) stock is rocketing more than 51% alongside heavy pre-market trading.</li>



<li>Blue World Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/bwaq-stock-quote/">BWAQ</a>) shares are soaring over 35% on Tuesday morning.</li>



<li>Baijiayun (NASDAQ:<a href="https://investorplace.com/stock-quotes/rtc-stock-quote/">RTC</a>) stock is surging more than 33% this morning.</li>



<li>ShiftPixy (NASDAQ:<a href="https://investorplace.com/stock-quotes/pixy-stock-quote/">PIXY</a>) shares are increasing over 31% alongside strong early morning trading.</li>



<li>QuantaSing (NASDAQ:<a href="https://investorplace.com/stock-quotes/qsg-stock-quote/">QSG</a>) stock is rising more than 24% on a <a href="https://www.nasdaq.com/press-release/quantasing-group-limited-announces-us-200-million-share-repurchase-program-2024-06-11">new share repurchase program</a>.</li>



<li>Recruiter.Com (NASDAQ:<a href="https://investorplace.com/stock-quotes/rcrt-stock-quote/">RCRT</a>) shares are gaining close to 20% on <a href="https://www.nasdaq.com/press-release/recruitercom-granted-continued-listing-nasdaq-hearings-panel-2024-06-11">continued Nasdaq listing</a>.</li>



<li>Viracta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/virx-stock-quote/">VIRX</a>) stock is climbing over 16% today.</li>



<li>CaliberCos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/">CWD</a>) shares are jumping more than 15% on Tuesday.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is heading over 15% higher on Tuesday morning.</li>



<li>Troops (NASDAQ:<a href="https://investorplace.com/stock-quotes/troo-stock-quote/">TROO</a>) shares are up more than 15% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Target Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/th-stock-quote/">TH</a>) stock is plummeting more than 27% on a <a href="https://www.nasdaq.com/press-release/target-hospitality-provides-update-south-texas-family-residential-center-located">terminated service agreement</a>.</li>



<li>TCTM Kids IT Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/tctm-stock-quote/">TCTM</a>) shares are crashing over 20% despite a lack of news this morning.</li>



<li>CoreCivic (NYSE:<a href="https://investorplace.com/stock-quotes/cxw-stock-quote/">CXW</a>) stock is diving almost 19% on a <a href="https://www.nasdaq.com/press-release/corecivic-receives-termination-notice-us-immigration-and-customs-enforcement-south">terminated service agreement</a>.</li>



<li>Contango Ore (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctgo-stock-quote/">CTGO</a>) shares are tumbling more than 18% on an <a href="https://www.nasdaq.com/press-release/contango-ore-announces-underwritten-public-offering-common-stock-2024-06-10">underwritten public offering</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is taking an over 18% beating <a href="https://investorplace.com/2024/06/why-is-big-tree-cloud-dsy-stock-up-96-today/">after rallying yesterday</a>.</li>



<li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) shares are sliding more than 16% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318384117&amp;type=PDF&amp;symbol=SPEC&amp;cdn=2ca70fab4e23ef5d9c11557ba510b0d5&amp;companyName=Spectaire+Holdings+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-10">proposed public offering</a>.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is falling over 15% this morning.</li>



<li>New Horizon Aircraft (NASDAQ:<a href="https://investorplace.com/stock-quotes/hovr-stock-quote/">HOVR</a>) shares are dropping more than 15% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318385886&amp;type=PDF&amp;symbol=HOVR&amp;cdn=2118b6378708ce5dbc010cd3e0c2dc12&amp;companyName=New+Horizon+Aircraft+Ltd.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-10">plans for a public share offering</a>.</li>



<li>Yext (NYSE:<a href="https://investorplace.com/stock-quotes/yext-stock-quote/">YEXT</a>) stock is slipping over 13% alongside its <a href="https://www.benzinga.com/news/earnings/24/06/39259544/yext-stock-falls-on-q1-results-acquisition-of-hearsay-systems-the-details">latest earnings report</a>.</li>



<li>ProKidney (NASDAQ:<a href="https://investorplace.com/stock-quotes/prok-stock-quote/">PROK</a>) shares close out our pre-market stock movers down more than 13% on a <a href="https://www.marketwatch.com/story/prokidney-shares-slip-12-on-125-million-offering-aa0db3f3?mod=investing">proposed stock offering</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-11th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) just reported results for the fourth quarter of 2023.<ul><li>Hoth Therapeutics reported earnings per share of -31 cents. This was above the analyst estimate for EPS of -51 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/hoth-stock-earnings-hoth-therapeutics-for-q4-of-2023/">HOTH Stock Earnings: Hoth Therapeutics Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HOTH Stock Earnings: Hoth Therapeutics Beats EPS for Q4 2023

Hoth Therapeutics (HOTH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

Hoth Therapeutics' Expansion and AI Integration Bolster Buy Rating

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is on the move Wednesday after the clinical-stage biopharmaceutical company <a href="https://finance.yahoo.com/news/hoth-therapeutics-partners-lts-therapy-103000382.html">announced a new partnership</a> with LTS Therapy Systems.



This partnership has the two companies working together to accelerate the development of Hoth Therapeutics&rsquo; candidate for Alzheimer&rsquo;s disease. HT-ALZ is currently pre-clinical with data suggesting it can restore cognitive functions and improve quality of life for Alzheimer&rsquo;s patients.



The agreement with LTS Therapy Systems will see it handle the production of the HT-ALZoral film prototype. This will aid Hoth Therapeutics as it seeks a future Investigational New Drug (IND) Application for clinical trials of the drug.



Hoth Therapeutics CEo Robb Knie said the following about this agreement.




&ldquo;Hoth is excited to announce this partnership and the next milestone in our development of HT-ALZ. We are leveraging LTS&rsquo;s expertise to develop and manufacture the oral film prototypes needed for this particular population and leveraging our positive preclinical results to advance our Alzheimer&rsquo;s therapeutic.&rdquo;




<h2>How This Affects HOTH Stock</h2>



New Alzheimer&rsquo;s treatments are a hot topic right now and this has traders taking notice of HOTH stock today. With that comes heavy trading as some 30 million shares change hands. That&rsquo;s well above the company&rsquo;s daily average trading volume of about 98,000 shares.



HOTH stock is down 2.9% as of Wednesday morning after rallying earlier today.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Wednesday! Among that is what has Rivian&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>), CrowdStrike&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) and Cohere&nbsp;in the news today. All of this info is ready to go at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/rivn-stock-alert-rivian-must-face-lawsuit-over-alleged-tesla-trade-secret-theft/">RIVN Stock Alert: Rivian Must Face Lawsuit Over Alleged Tesla Trade Secret Theft</a></li>



<li><a href="https://investorplace.com/2024/07/crowdstrike-outage-alert-crwd-shares-dip-as-crowdstrike-identifies-bug/">CrowdStrike Outage Alert: CRWD Shares Dip as CrowdStrike Identifies Bug</a></li>



<li><a href="https://investorplace.com/2024/07/cohere-layoffs-2024-what-to-know-about-the-latest-ai-job-cuts/">Cohere Layoffs 2024: What to Know About the Latest AI Job Cuts</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">Why Is Hoth Therapeutics (HOTH) Stock Moving Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Hoth Therapeutics (HOTH) Stock Moving Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into all of the biggest pre-market stock movers on Thursday morning!



Moving stocks this morning are earnings reports, a public debut, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is rocketing more than 211% after announcing a <a href="https://www.globenewswire.com/news-release/2024/07/24/2918366/0/en/Psyence-Biomed-Announces-Export-of-Nature-Derived-Psilocybin-to-Australia-and-Provides-Update-on-Upcoming-Phase-IIb-Trial.html">psilocybin export to Australia</a> and providing a clinical trial update.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are soaring over 91% after <a href="https://www.nasdaq.com/press-release/tivic-health-expands-intellectual-property-portfolio-2024-07-23">expanding its intellectual property portfolio</a>.</li>



<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock is surging more than 48% <a href="https://www.wboy.com/business/press-releases/accesswire/891946/bloomz-inc-announces-pricing-of-5-38-million-initial-public-offering/">following its recent public debut</a>.</li>



<li>Cero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are rising over 32% alongside heavy pre-market trading.</li>



<li>Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>) stock is increasing more than 17% after <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html">releasing its Q2 earnings report</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are gaining close to 17% with strong early morning trading today.</li>



<li>Indivior (NASDAQ:<a href="https://investorplace.com/stock-quotes/indv-stock-quote/">INDV</a>) stock is heading over 14% higher on <a href="https://www.marketwatch.com/story/indivior-shares-jump-on-increased-revenue-100m-share-buyback-5cd4e573?mod=newsviewer_click">Q2 revenue growth</a> and a share buyback.</li>



<li>Signing Day Sports (NYSEMKT:<a href="https://investorplace.com/stock-quotes/sgn-stock-quote/">SGN</a>) shares are jumping more than 14% without any clear news this morning.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) stock is getting a 14% boost on Thursday morning.</li>



<li>Stellus Capital Investment (NYSE:<a href="https://investorplace.com/stock-quotes/scm-stock-quote/">SCM</a>) shares are up over 12% despite a lack of news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>2U (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is plummeting more than 68% with a <a href="https://www.nasdaq.com/press-release/2u-takes-strategic-action-significantly-strengthen-balance-sheet-and-position-company">Chapter 11 bankruptcy filing</a>.</li>



<li>Edwards Lifesciences (NYSE:<a href="https://investorplace.com/stock-quotes/ew-stock-quote/">EW</a>) shares are diving over 22% alongside <a href="https://www.nasdaq.com/press-release/edwards-lifesciences-reports-second-quarter-results-2024-07-24">lackluster Q2 results</a>.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) stock is tumbling more than 19% following a rally yesterday.</li>



<li>MaxLinear (NASDAQ:<a href="https://investorplace.com/stock-quotes/mxl-stock-quote/">MXL</a>) shares are taking an over 18% beating after <a href="https://finance.yahoo.com/news/maxlinear-inc-announces-second-quarter-200500103.html">releasing its Q2 earnings report</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) stock is sliding more than 17% after a rally yesterday.</li>



<li>IF Bancorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/iroq-stock-quote/">IROQ</a>) shares are falling over 16% despite a lack of news this morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is dropping more than 16% <a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">alongside recent volatility</a>.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) shares are retreating over 15% <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">with recent volatility</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">after rallying yesterday</a>.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) shares close out our pre-market stock movers down over 14% <a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">following a Wednesday rally</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Hoth Therapeutics (HOTH – Research Report) today and set a price target of $4.00. ...

Buy Rating Affirmed for Hoth Therapeutics on Strategic Partnerships and Promising Alzheimer's Treatment Advances

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Hoth Therapeutics (HOTH – Research Report), Rewalk R...

Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)

Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug

ALLR

ATCH

ATIP

ATPC

AZTR

BBLG

BWAQ

CERO

CJET

CONN

CTGO

DRMA

DTCK

HOVR

INDV

IROQ

KITT

LFWD

NIVF

NUZE

PIRS

PIXY

PMNT

PROK

RANI

RCRT

RIVN

SAGE

SLNA

SLRX

SOAR

SPEC

TCTM

TIVC

TROO

TWOU

VIRX

VKTX

VSME

VSTM

VTAK

YEXT

Press Releases

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Offerings

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Contracts

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Hoth Therapeutics

Hoth Therapeutics (HOTH) Forecast

Hoth Therapeutics (NASDAQ:HOTH) Stock, Quote.Headers.trade-ideas